Immune Checkpoint Inhibitors and Chemoradiation for Limited-Stage Small Cell Lung Cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune Checkpoint Inhibitors and Chemoradiation for Limited-Stage Small Cell Lung Cancer
Authors
Keywords
-
Journal
CURRENT TREATMENT OPTIONS IN ONCOLOGY
Volume 23, Issue 8, Pages 1104-1120
Publisher
Springer Science and Business Media LLC
Online
2022-06-18
DOI
10.1007/s11864-022-00989-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Small-cell lung cancer
- (2021) Charles M. Rudin et al. Nature Reviews Disease Primers
- Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451
- (2021) Taofeek K. Owonikoko et al. JOURNAL OF CLINICAL ONCOLOGY
- Radiotherapy, immunotherapy, and the tumour microenvironment: Turning an immunosuppressive milieu into a therapeutic opportunity
- (2021) N.E. Donlon et al. CANCER LETTERS
- Consolidation nivolumab and ipilimumab versus observation in limited-disease small cell lung cancer after chemo-radiotherapy – Results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial
- (2021) S. Peters et al. ANNALS OF ONCOLOGY
- KEYLYNK-013: A phase 3 study of pembrolizumab in combination with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy in patients with newly diagnosed limited-stage SCLC.
- (2021) Andreas Rimner et al. JOURNAL OF CLINICAL ONCOLOGY
- TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer
- (2021) Zhouhong Ge et al. Frontiers in Immunology
- PL02.01 Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study
- (2021) M. Johnson et al. Journal of Thoracic Oncology
- Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L)
- (2021) Motoko Tachihara et al. Cancer Management and Research
- The Promise of Combining Radiation Therapy With Immunotherapy
- (2020) Justin C. Jagodinsky et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).
- (2020) Delvys Rodriguez-Abreu et al. JOURNAL OF CLINICAL ONCOLOGY
- NRG Oncology/Alliance LU005: A phase II/III randomized clinical trial of chemoradiation versus chemoradiation plus atezolizumab in limited stage small cell lung cancer.
- (2020) Helen J. Ross et al. JOURNAL OF CLINICAL ONCOLOGY
- Does radiation increase the risk of immunotherapy related pneumonitis in cancer patients with thorax radiotherapy combined immune checkpoint inhibitors: A meta-analysis.
- (2020) Yamin Jie et al. JOURNAL OF CLINICAL ONCOLOGY
- Radiation Therapy for Small Cell Lung Cancer: An ASTRO Clinical Practice Guideline
- (2020) Charles B. Simone et al. Practical Radiation Oncology
- Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC
- (2020) James W. Welsh et al. Journal of Thoracic Oncology
- Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study
- (2020) Suchita Pakkala et al. Journal for ImmunoTherapy of Cancer
- Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
- (2019) Triparna Sen et al. Cancer Discovery
- Durvalumab in Combination with Olaparib in Patients with Relapsed Small Cell Lung Cancer: Results from a Phase II Study
- (2019) Anish Thomas et al. Journal of Thoracic Oncology
- Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer
- (2019) Willemijn S. M. E. Theelen et al. JAMA Oncology
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- (2019) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
- (2019) Luis Paz-Ares et al. LANCET
- Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study
- (2019) Suresh Senan et al. Clinical Lung Cancer
- Abscopal effect in lung cancer: three case reports and a concise review
- (2019) Elena Garelli et al. Immunotherapy
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
- (2018) Leora Horn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association of Chemoradiotherapy With Outcomes Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer
- (2018) Ahmed Salem et al. JAMA Oncology
- P1.15-004 An Open-Label, Multitumor Phase II Basket Study of Olaparib and Durvalumab (MEDIOLA): Results in Patients with Relapsed SCLC
- (2017) M. Krebs et al. Journal of Thoracic Oncology
- Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial
- (2017) Corinne Faivre-Finn et al. LANCET ONCOLOGY
- Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
- (2017) Narek Shaverdian et al. LANCET ONCOLOGY
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment advances in small cell lung cancer (SCLC)
- (2017) Saiama N. Waqar et al. PHARMACOLOGY & THERAPEUTICS
- Systematic review of case reports on the abscopal effect
- (2016) Yazan Abuodeh et al. CURRENT PROBLEMS IN CANCER
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial
- (2015) Encouse B Golden et al. LANCET ONCOLOGY
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
- (2015) Christina Twyman-Saint Victor et al. NATURE
- STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors
- (2014) Liufu Deng et al. IMMUNITY
- Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1
- (2012) Lauren Averett Byers et al. Cancer Discovery
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More